The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces.
Colitis, ulcerative
Fecal calprotectin
Latex agglutination turbidimetric immunoassay
Mucosal healing
Quantitative fecal immunochemical test
Journal
Intestinal research
ISSN: 1598-9100
Titre abrégé: Intest Res
Pays: Korea (South)
ID NLM: 101572802
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
16
07
2018
accepted:
23
10
2018
pubmed:
14
12
2018
medline:
14
12
2018
entrez:
14
12
2018
Statut:
ppublish
Résumé
Fecal calprotectin (Fcal) as well as the fecal immunochemical test (FIT) are useful biomarkers for detecting activity and mucosal healing in inflammatory bowel diseases. Here, we report the performance of simultaneous measurements of Fcal and FIT for ulcerative colitis (UC) patients using the newly-developed latex agglutination turbidimetric immunoassay (LATIA) system. Fcal and hemoglobin were measured by the LATIA system in 152 UC patients who underwent colonoscopy. Fcal was also quantified with a conventional enzyme-linked immunosorbent assay (ELISA). Fecal markers were evaluated in conjunction with the mucosal status of UC, which was assessed via the Mayo endoscopic subscore (MES) classification. The LATIA system could quantify calprotectin and hemoglobin simultaneously with the same fecal samples within 10 minutes. The values of the Fcal-LATIA closely correlated with those of the Fcal-ELISA (Spearman rank correlation coefficient, r=0.84; P<0.0001). The values of Fcal for each assay and the FIT all significantly correlated with the MESs (Spearman rank correlation coefficient, Fcal-LATIA: r=0.58, Fcal-ELISA: r=0.55, and FIT: r=0.72). The mucosal healing predictability (determined by an MES of 0 alone) of the Fcal-LATIA, Fcal-ELISA, and FIT-LATIA with the cutoffs determined by receiver operating characteristic curve analysis was 0.79, 0.78, and 0.92 for sensitivity, respectively, and 0.78, 0.69, and 0.73 for specificity, respectively. The performance of the novel Fcal-LATIA was equivalent to that of the conventional Fcal assay. Simultaneous measurements with FITs would promote the clinical relevance of fecal biomarkers in UC.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
Fecal calprotectin (Fcal) as well as the fecal immunochemical test (FIT) are useful biomarkers for detecting activity and mucosal healing in inflammatory bowel diseases. Here, we report the performance of simultaneous measurements of Fcal and FIT for ulcerative colitis (UC) patients using the newly-developed latex agglutination turbidimetric immunoassay (LATIA) system.
METHODS
METHODS
Fcal and hemoglobin were measured by the LATIA system in 152 UC patients who underwent colonoscopy. Fcal was also quantified with a conventional enzyme-linked immunosorbent assay (ELISA). Fecal markers were evaluated in conjunction with the mucosal status of UC, which was assessed via the Mayo endoscopic subscore (MES) classification.
RESULTS
RESULTS
The LATIA system could quantify calprotectin and hemoglobin simultaneously with the same fecal samples within 10 minutes. The values of the Fcal-LATIA closely correlated with those of the Fcal-ELISA (Spearman rank correlation coefficient, r=0.84; P<0.0001). The values of Fcal for each assay and the FIT all significantly correlated with the MESs (Spearman rank correlation coefficient, Fcal-LATIA: r=0.58, Fcal-ELISA: r=0.55, and FIT: r=0.72). The mucosal healing predictability (determined by an MES of 0 alone) of the Fcal-LATIA, Fcal-ELISA, and FIT-LATIA with the cutoffs determined by receiver operating characteristic curve analysis was 0.79, 0.78, and 0.92 for sensitivity, respectively, and 0.78, 0.69, and 0.73 for specificity, respectively.
CONCLUSIONS
CONCLUSIONS
The performance of the novel Fcal-LATIA was equivalent to that of the conventional Fcal assay. Simultaneous measurements with FITs would promote the clinical relevance of fecal biomarkers in UC.
Identifiants
pubmed: 30541228
pii: ir.2018.00086
doi: 10.5217/ir.2018.00086
pmc: PMC6505093
doi:
Types de publication
Journal Article
Langues
eng
Pagination
202-209Références
N Engl J Med. 2002 Aug 8;347(6):417-29
pubmed: 12167685
Cancer. 2003 May 15;97(10):2420-4
pubmed: 12733140
Gastroenterology. 2005 Aug;129(2):422-8
pubmed: 16083699
Am J Gastroenterol. 2005 Nov;100(11):2519-25
pubmed: 16279909
J Clin Microbiol. 1992 Jan;30(1):96-8
pubmed: 1734072
Gastroenterology. 2007 Aug;133(2):412-22
pubmed: 17681162
Inflamm Bowel Dis. 2009 Dec;15(12):1851-8
pubmed: 19462421
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1492-501
pubmed: 21576271
Inflamm Bowel Dis. 2012 Dec;18(12):2218-24
pubmed: 22344983
Am J Gastroenterol. 2013 Jan;108(1):83-9
pubmed: 23007005
Inflamm Bowel Dis. 2013 Apr;19(5):1043-52
pubmed: 23511035
J Gastroenterol Hepatol. 2014;29(7):1406-12
pubmed: 24635100
United European Gastroenterol J. 2014 Feb;2(1):30-7
pubmed: 24918006
Am J Gastroenterol. 2015 Jun;110(6):873-80
pubmed: 25823769
Am J Gastroenterol. 2015 Jun;110(6):802-19; quiz 820
pubmed: 25964225
J Crohns Colitis. 2016 Jun;10(6):687-94
pubmed: 26802083
Clin Chim Acta. 2016 May 1;456:1-6
pubmed: 26908083
Eur J Clin Invest. 2016 Oct;46(10):825-32
pubmed: 27438629
Clin Lab. 2016 Nov 1;62(11):2085-2089
pubmed: 28164666
Gastroenterology. 2017 Aug;153(2):439-447.e2
pubmed: 28483499
Dig Liver Dis. 2017 Sep;49(9):991-996
pubmed: 28587751
Clin Gastroenterol Hepatol. 2017 Nov;15(11):1742-1749.e2
pubmed: 28606846
Inflamm Bowel Dis. 2017 Sep;23(9):1643-1649
pubmed: 28644184
Gut Liver. 2018 Mar 15;12(2):142-148
pubmed: 28873508
J Crohns Colitis. 2018 Jan 5;12(1):71-76
pubmed: 28961792
Arch Pathol Lab Med. 2018 Jan;142(1):75-82
pubmed: 28967803
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Clin Chem. 1988 Sep;34(9):1763-6
pubmed: 3416425
J Clin Lab Immunol. 1986 Feb;19(2):99-103
pubmed: 3514917